Which has preferable earnings and valuation, BVS or ELMD?

Bioventus has higher revenue and earnings than Electromed. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.17 $22.73M $0.77 19.06 Electromed $71.75M 4.72 $5.15M $1.17 34.93

Is BVS or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat Electromed's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% Electromed 11.34% 15.71% 13.37%

Do analysts prefer NNNN or ELMD?

Electromed has a consensus price target of $37.50, suggesting a potential downside of 8.25%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has higher valuation and earnings, NNNN or ELMD?

Anbio Biotechnology has higher earnings, but lower revenue than Electromed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 128.92 $6.40M N/A N/A Electromed $71.75M 4.72 $5.15M $1.17 34.93

Electromed (ELMD) Competitors

$40.87 -0.55 (-1.33%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$40.82 -0.05 (-0.13%)

As of 08/19/2026 07:30 PM Eastern

Compare

ELMD vs. DRTS, PRCT, STAA, BVS, and NNNN

Should you buy Electromed stock or one of its competitors? Electromed's main competitors and comparable companies include Alpha Tau Medical (DRTS), PROCEPT BioRobotics (PRCT), STAAR Surgical (STAA), Bioventus (BVS), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Electromed compare to Alpha Tau Medical?

Electromed (NYSE:ELMD) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Alpha Tau Medical had 12 more articles in the media than Electromed. MarketBeat recorded 12 mentions for Alpha Tau Medical and 0 mentions for Electromed. Electromed's average media sentiment score of 0.00 beat Alpha Tau Medical's score of -0.25 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Neutral
Alpha Tau Medical	Neutral

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 8.25%. Alpha Tau Medical has a consensus price target of $12.80, indicating a potential downside of 11.54%. Given Electromed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Electromed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Electromed has a net margin of 11.34% compared to Alpha Tau Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Alpha Tau Medical	N/A	-138.12%	-81.68%

40.8% of Electromed shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Electromed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Electromed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.72	$5.15M	$1.17	34.93
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A

Summary

Electromed beats Alpha Tau Medical on 11 of the 15 factors compared between the two stocks.

How does Electromed compare to PROCEPT BioRobotics?

Electromed (NYSE:ELMD) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Electromed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to PROCEPT BioRobotics' net margin of -32.53%. Electromed's return on equity of 15.71% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

40.8% of Electromed shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Electromed has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.72	$5.15M	$1.17	34.93
PROCEPT BioRobotics	$308.05M	4.07	-$95.57M	-$1.94	N/A

In the previous week, PROCEPT BioRobotics had 44 more articles in the media than Electromed. MarketBeat recorded 44 mentions for PROCEPT BioRobotics and 0 mentions for Electromed. PROCEPT BioRobotics' average media sentiment score of 0.12 beat Electromed's score of 0.00 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
PROCEPT BioRobotics	Neutral

Electromed presently has a consensus target price of $37.50, suggesting a potential downside of 8.25%. PROCEPT BioRobotics has a consensus target price of $28.00, suggesting a potential upside of 27.80%. Given PROCEPT BioRobotics' higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

Summary

Electromed beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

How does Electromed compare to STAAR Surgical?

Electromed (NYSE:ELMD) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, STAAR Surgical had 17 more articles in the media than Electromed. MarketBeat recorded 17 mentions for STAAR Surgical and 0 mentions for Electromed. STAAR Surgical's average media sentiment score of 0.35 beat Electromed's score of 0.00 indicating that STAAR Surgical is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
STAAR Surgical	Neutral

Electromed presently has a consensus price target of $37.50, suggesting a potential downside of 8.25%. STAAR Surgical has a consensus price target of $28.40, suggesting a potential upside of 15.17%. Given STAAR Surgical's higher probable upside, analysts plainly believe STAAR Surgical is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
STAAR Surgical	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.08

Electromed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

40.8% of Electromed shares are held by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are held by institutional investors. 10.5% of Electromed shares are held by insiders. Comparatively, 39.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Electromed has a net margin of 11.34% compared to STAAR Surgical's net margin of 1.13%. Electromed's return on equity of 15.71% beat STAAR Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
STAAR Surgical	1.13%	9.05%	6.99%

Electromed has higher earnings, but lower revenue than STAAR Surgical. Electromed is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.72	$5.15M	$1.17	34.93
STAAR Surgical	$239.44M	5.16	-$80.45M	$0.07	352.29

Summary

STAAR Surgical beats Electromed on 10 of the 17 factors compared between the two stocks.

How does Electromed compare to Bioventus?

Bioventus (NASDAQ:BVS) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Bioventus had 7 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Bioventus and 0 mentions for Electromed. Bioventus' average media sentiment score of 0.17 beat Electromed's score of 0.00 indicating that Bioventus is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventus	Neutral
Electromed	Neutral

Electromed has a net margin of 11.34% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Electromed	11.34%	15.71%	13.37%

62.9% of Bioventus shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bioventus has higher revenue and earnings than Electromed. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.17	$22.73M	$0.77	19.06
Electromed	$71.75M	4.72	$5.15M	$1.17	34.93

Bioventus has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Electromed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Bioventus presently has a consensus target price of $16.80, suggesting a potential upside of 14.44%. Electromed has a consensus target price of $37.50, suggesting a potential downside of 8.25%. Given Bioventus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Bioventus beats Electromed on 11 of the 16 factors compared between the two stocks.

How does Electromed compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

40.8% of Electromed shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to Anbio Biotechnology's net margin of 0.00%. Electromed's return on equity of 15.71% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Electromed	11.34%	15.71%	13.37%

Anbio Biotechnology has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market. Comparatively, Electromed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Electromed has a consensus price target of $37.50, suggesting a potential downside of 8.25%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Anbio Biotechnology had 3 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Anbio Biotechnology and 0 mentions for Electromed. Anbio Biotechnology's average media sentiment score of 0.04 beat Electromed's score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Electromed	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than Electromed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	128.92	$6.40M	N/A	N/A
Electromed	$71.75M	4.72	$5.15M	$1.17	34.93

Summary

Electromed beats Anbio Biotechnology on 9 of the 14 factors compared between the two stocks.

Get Electromed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELMD vs. The Competition

Export

Metric	Electromed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$338.40M	$5.90B	$7.16B	$24.19B
Dividend Yield	N/A	1.75%	2.55%	3.73%
P/E Ratio	54.49	26.18	268.96	30.14
Price / Sales	4.72	65.79	626.47	20.90
Price / Cash	41.36	33.29	78.23	31.97
Price / Book	8.01	6.06	13.16	6.84
Net Income	$5.15M	$149.38M	$3.47B	$1.07B
7 Day Performance	-3.93%	1.65%	2.27%	-0.57%
1 Month Performance	-0.02%	6.65%	5.35%	2.97%
1 Year Performance	108.41%	10.24%	29.21%	18.26%

Electromed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELMD Electromed	0.6218 of 5 stars	$40.87 -1.3%	$37.50 -8.2%	+113.3%	$338.40M	$71.75M	54.49	160	Positive News
DRTS Alpha Tau Medical	1.2522 of 5 stars	$14.22 +0.5%	$12.80 -10.0%	+363.8%	$1.29B	N/A	N/A	80
PRCT PROCEPT BioRobotics	3.945 of 5 stars	$21.75 +3.1%	$28.00 +28.8%	-44.8%	$1.24B	$308.05M	N/A	430	Trending News
STAA STAAR Surgical	3.0786 of 5 stars	$24.08 0.0%	$28.40 +17.9%	-11.8%	$1.20B	$339.59M	345.34	1,211	Analyst Forecast
BVS Bioventus	4.3348 of 5 stars	$14.31 +3.1%	$16.80 +17.4%	+100.5%	$1.20B	$568.09M	18.56	1,200	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELMD) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Electromed (ELMD) Competitors

ELMD vs. DRTS, PRCT, STAA, BVS, and NNNN

How does Electromed compare to Alpha Tau Medical?

Summary

How does Electromed compare to PROCEPT BioRobotics?

Summary

How does Electromed compare to STAAR Surgical?

Summary

How does Electromed compare to Bioventus?

Summary

How does Electromed compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Electromed (ELMD) Competitors

ELMD vs. DRTS, PRCT, STAA, BVS, and NNNN

How does Electromed compare to Alpha Tau Medical?

Does the media favor ELMD or DRTS?

Do analysts prefer ELMD or DRTS?

Is ELMD or DRTS more profitable?

Do institutionals & insiders have more ownership in ELMD or DRTS?

Which has more risk and volatility, ELMD or DRTS?

Which has better valuation and earnings, ELMD or DRTS?

Summary

How does Electromed compare to PROCEPT BioRobotics?

Which has more risk & volatility, ELMD or PRCT?

Is ELMD or PRCT more profitable?

Do institutionals and insiders have more ownership in ELMD or PRCT?

Which has higher valuation & earnings, ELMD or PRCT?

Does the media favor ELMD or PRCT?

Do analysts prefer ELMD or PRCT?

Summary

How does Electromed compare to STAAR Surgical?

Does the media favor ELMD or STAA?

Do analysts recommend ELMD or STAA?

Which has more volatility & risk, ELMD or STAA?

Do institutionals and insiders hold more shares of ELMD or STAA?

Is ELMD or STAA more profitable?

Which has stronger valuation and earnings, ELMD or STAA?

Summary

How does Electromed compare to Bioventus?

Does the media refer more to BVS or ELMD?

Is BVS or ELMD more profitable?

Do insiders & institutionals have more ownership in BVS or ELMD?

Which has preferable earnings and valuation, BVS or ELMD?

Which has more risk and volatility, BVS or ELMD?

Do analysts rate BVS or ELMD?

Summary

How does Electromed compare to Anbio Biotechnology?

Do institutionals and insiders have more ownership in NNNN or ELMD?

Is NNNN or ELMD more profitable?

Which has more volatility & risk, NNNN or ELMD?

Do analysts prefer NNNN or ELMD?

Does the media refer more to NNNN or ELMD?

Which has higher valuation and earnings, NNNN or ELMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools